DNA Sciences Soars 16.85% Post Reverse Stock Split

On June 5, 2025, DNA Sciences surged 16.85% in pre-market trading, marking a significant rise in its stock price.

DNA Sciences recently announced a 1-for-15 reverse stock split, effective June 2, 2025. This move was aimed at regaining compliance with Nasdaq's minimum bid price requirement of $1.00. The reverse split reduced the number of outstanding shares from approximately 7.8 million to 519 thousand, while maintaining the trading symbol "APDN."

The company also rescheduled its intra-quarter webcast and investor update call to June 17, 2025. This adjustment was made to accommodate the implementation of the reverse stock split. The webcast will feature prepared remarks from management and a Q&A session with analysts and investors.

In its second quarter fiscal 2025 financial results, DNA Sciences reported total revenues of $983K, reflecting a 6% year-over-year increase. The LineaRx segment experienced a notable 44% revenue increase, while MDx Testing Services revenue declined by 33%. The company reported a net loss of $3.3 million, an improvement from the $4.5 million loss in the previous year.